Payment overview · 2025
General Payments
$1,206.87
33 reported records · 16 companies
Healthcare provider profile · identity verified
Brian A Pollock, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · CUYAHOGA FALLS, OH · NPI 1558319780
Verified facts
What the public records show
CMS Open Payments records show Brian A Pollock, D.O. received $1,206.87 in general payments during 2025 across 33 reported records.
Novo Nordisk Inc accounted for 14.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $175.74 | 14.6% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $165.80 | 13.7% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $152.25 | 12.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $140.12 | 11.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $139.61 | 11.6% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $114.08 | 9.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $48.04 | 4.0% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $40.74 | 3.4% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $39.48 | 3.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $37.44 | 3.1% | 2 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $36.95 | 3.1% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $33.98 | 2.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $31.76 | 2.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.34 | 1.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.74 | 1.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.80 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,206.87 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $192.99 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $175.74 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $165.80 | 3 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $124.72 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $121.36 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $48.04 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $39.48 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $37.44 | 2 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $36.95 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $33.98 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $33.98 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $31.76 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $31.76 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.34 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.25 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.25 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.25 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $9.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
134 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 396 | 90 |
| Levothyroxine Sodium | Levothyroxine Sodium | 205 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 204 | 52 |
| Amlodipine Besylate | Amlodipine Besylate | 175 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 153 | 33 |
| Eliquis | Apixaban | 134 | 32 |
| Furosemide | Furosemide | 134 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 124 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 121 | 33 |
| Gabapentin | Gabapentin | 116 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 112 | 34 |
| Potassium Chloride | Potassium Chloride | 110 | 28 |
| Losartan Potassium | Losartan Potassium | 106 | 32 |
| Lisinopril | Lisinopril | 105 | 31 |
| Omeprazole | Omeprazole | 96 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 83 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 77 | 18 |
| Mirtazapine | Mirtazapine | 74 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 70 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 69 | 31 |
| Carvedilol | Carvedilol | 63 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 29 |
| Trazodone Hcl | Trazodone Hcl | 55 | 19 |
| Metformin Hcl | Metformin Hcl | 51 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 11 |
| Baclofen | Baclofen | 49 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 49 | 16 |
| Sertraline Hcl | Sertraline Hcl | 49 | 17 |
| Finasteride | Finasteride | 46 | suppressed |
| Risperidone | Risperidone | 45 | suppressed |
| Memantine Hcl | Memantine Hcl | 44 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 41 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 40 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 37 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 35 | suppressed |
| Meloxicam | Meloxicam | 34 | 11 |
| Allopurinol | Allopurinol | 33 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | suppressed |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Prednisone | Prednisone | 33 | 25 |
| Montelukast Sodium | Montelukast Sodium | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Torsemide | Torsemide | 29 | 13 |
| Tramadol Hcl | Tramadol Hcl | 29 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 23 |
| Modafinil | Modafinil | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | 11 |
| Lorazepam | Lorazepam | 22 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 14 |
| Famotidine | Famotidine | 18 | suppressed |
| Methadone Hcl | Methadone Hcl | 18 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 18 | suppressed |
| Simvastatin | Simvastatin | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Sulfasalazine | Sulfasalazine | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | 12 |
| Alprazolam | Alprazolam | 15 | suppressed |
| Azithromycin | Azithromycin | 15 | 13 |
| Calcium Acetate | Calcium Acetate | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Cefadroxil | Cefadroxil | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 12 | suppressed |
| Ozempic | Semaglutide | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,206.87 · 33 records | Novo Nordisk Inc | ABRYSVO, BREZTRI, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, FUROSCIX, GARDASIL 9, GVOKE HYPOPEN, JARDIANCE, MOUNJARO, NUCALA, OTEZLA, Ozempic, PREVNAR 20, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, VRAYLAR, Veozah, ZAVZPRET, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error